Phathom Pharmaceuticals
PHAT
6.81
+0.03
+0.44%
Phathom Pharmaceuticals
US · PHAT
#3684 by market cap
Listed 2019
6.81
+0.03
+0.44%
Live - 5344 symbols - heartbeat 37s ago
· 2026-10-08 07:12
Pre-market
7.00
+2.79%
After-hours
6.80
-0.15%
- Market cap
- 550.94M
- P/E (TTM)i
- -5.45
- P/Bi
- -1.60
- EPSi
- -3.03
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on PHAT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
19.29 +183.3%
Price target rangecurrent 6.81
Low10.00
Avg19.29
High26.00
Buy 86%
Hold 14%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-21 | H.C. Wainwright | -- | BUY | 26.00 |
| 2026-09-09 | Leerink Partners | -- | HOLD | 10.00 |
| 2026-08-17 | Barclays | -- | BUY | 14.00 |
| 2026-07-31 | Craig-Hallum | -- | BUY | 20.00 |
| 2026-07-31 | Raymond James | -- | BUY | 21.00 |
| 2026-07-31 | Guggenheim | -- | BUY | 22.00 |
| 2026-07-31 | H.C. Wainwright | -- | BUY | 26.00 |
| 2026-07-30 | Needham | -- | BUY | 22.00 |
| 2026-07-21 | Needham | -- | BUY | 28.00 |
| 2026-07-21 | Guggenheim | -- | BUY | 25.00 |
| 2026-07-13 | Craig-Hallum | -- | BUY | -- |
| 2026-06-23 | Craig-Hallum | -- | BUY | -- |
| 2026-06-17 | H.C. Wainwright | -- | BUY | 26.00 |
| 2026-06-01 | Needham | -- | BUY | 28.00 |
| 2026-05-26 | Needham | -- | BUY | 28.00 |
| 2026-05-19 | Needham | -- | BUY | 28.00 |
| 2026-05-15 | Barclays | -- | BUY | 18.00 |
| 2026-05-01 | H.C. Wainwright | -- | BUY | 26.00 |
| 2026-04-30 | Needham | -- | BUY | 28.00 |
| 2026-04-30 | Goldman Sachs | -- | HOLD | -- |
| 2026-04-30 | Guggenheim | -- | BUY | 25.00 |
| 2026-04-28 | Craig-Hallum | -- | BUY | -- |
| 2026-04-16 | Needham | -- | BUY | 28.00 |
| 2026-03-27 | Barclays | -- | BUY | 18.00 |
| 2026-02-27 | H.C. Wainwright | -- | BUY | 26.00 |
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Barclays moved from Hold to Buy on 2026-03-27.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-27 | Barclays | HOLD → BUY | 18.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-30 | -- | ±26.81% | -22.42% (in line) |
| 2026/Q1 | 2026-04-30 | -- | ±23.87% | -4.92% (in line) |
| 2025/Q4 | 2026-02-26 | -- | ±32.67% | +10.06% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±30.03% | -1.63% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±36.68% | +8.29% (in line) |
| 2025/Q1 | 2025-05-01 | -- | ±34.85% | -21.68% (in line) |
| 2024/Q4 | 2025-03-06 | -- | ±37.20% | -2.96% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±21.86% | +2.78% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±28.06% | +8.70% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±20.05% | -0.10% (in line) |
| 2023/Q4 | 2024-03-07 | -- | -- | -6.58% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:12:41 · For reference only, not investment advice and not tailored to your situation.